Oluwole Jegede

Dr. Oluwole Jegede

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Psychiatry Research
Verified
Journal Article
Closed access
OJOluwole Jegede
Oluwole Jegede
GRGreg Rhee
Greg Rhee
ESElina A. Stefanovics
Elina A. Stefanovics
BZBin Zhou
Bin Zhou
RRRobert A. Rosenheck
Robert A. Rosenheck

15 July 2020 in International Journal of Social Psychiatry
Verified
Journal Article
Closed access
PDF file
OJOluwole Jegede
Oluwole Jegede
SMSrinivas Muvvala
Srinivas Muvvala
EKEmmanuel Katehis
Emmanuel Katehis
SPSaad Paul
Saad Paul
ASAyorinde Soipe
Ayorinde Soipe
AJAyodeji Jolayemi
Ayodeji Jolayemi
The application of the structural vulnerability construct in medicine addresses social structures as the source of health inequities. Evidence demonstrates structural vulnerability as the meta-problem that underlie health disparities faced by underrepresented minorities who are less likely to access care and face stigma for substance use disorders (SUDs). The objective of this study is to assess perceived vulnerability at the structural and interpersonal levels depicted by barriers to care, treatment-related stigma and anticipated discrimination among African Americans with SUDs. Participants were 58 consecutive African American patients receiving treatment at an acute inpatient substance use service of a teaching hospital from September to November 2019. Structural vulnerability, barriers to care and anticipated discrimination were assessed using the structural vulnerability assessment tool, Barriers to Access Care Evaluation (BACE) and the Questionnaire on Anticipated Discrimination (QUAD) surveys, respectively. The total mean scores for the BACE-3, BACE-3 stigma subscale and QUAD were 1.0, 1.15 and 1.51, respectively. No statistically significant differences are found in the stigma subscale based on gender and psychiatric diagnosis (p > .05). Furthermore, there were also no gender, age or differences based on psychiatric diagnosis across both the BACE and QUAD scales. Structural and interpersonal factors remain sources of vulnerability, stigma and anticipated discrimination for African Americans with SUDs and comorbid mental illness.

27 March 2023 in The International Journal of Psychiatry in Medicine
Verified
Journal Article
Closed access
DLDexter L Louie
Dexter L Louie
OJOluwole Jegede
Oluwole Jegede
GHGretchen L Hermes
Gretchen L Hermes
Though clinical guidelines and policies discourage the chronic prescribing of benzodiazepines, rates of prescribing have continued to rise in the United States with an estimated 65.9 million office visits per year made for this purpose. Quietly, we have become a nation on benzodiazepines. There are numerous reasons for this discrepancy between official recommendations on the one hand, and actual clinical practice on the other. Drawing from the literature, we argue that while patients and providers both shoulder some of the responsibility, they cannot be solely blamed. Rather, policies and guidelines regarding benzodiazepine prescribing have become out of touch with the clinical reality that benzodiazepines are now deeply entrenched in modern medicine. We propose that guidelines regarding benzodiazepines need to reconsider how to apply concepts such as harm reduction and other lessons learned in the opioid epidemic in order to help physicians manage this increasingly pressing problem affecting millions of Americans.

10 February 2023 in Psychiatry Research
Verified
Journal Article
Closed access
TBTanner Bommersbach
Tanner Bommersbach
GRGreg Rhee
Greg Rhee
OJOluwole Jegede
Oluwole Jegede
RRRobert A. Rosenheck
Robert A. Rosenheck

10 August 2024 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
OJOluwole Jegede
Oluwole Jegede
JAJoao P. De Aquino
Joao P. De Aquino
CHConnie Hsaio
Connie Hsaio
ECEbony Caldwell
Ebony Caldwell
MFMelissa C. Funaro
Melissa C. Funaro
SMSrinivas B. Muvvala
Srinivas B. Muvvala
Background: The clinical implications of high potency synthetic opioids (HPSO) on medications for opioid use disorder (MOUDs) are not well understood. Although pharmacological interactions are plausible, the clinical significance of such interaction has not been systematically elucidated. This scoping review investigates the relationship between HPSO exposure and various MOUD treatment outcomes. Methods: We followed PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews) for scoping reviews with extensive a priori search strategy of databases: MEDLINE, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane. Results: From 9149 studies, 34 fulfilled the inclusion criteria. Synthesized data reveal several critical insights: First, there is a variable but high occurrence (38%–80%) of HPSO usage among individuals with MOUDs. Second, MOUDs are linked to a decreased risk of overdoses and deaths associated with HPSO. Third, HPSO consumption is correlated with the risk of precipitated withdrawal when starting buprenorphine. Fourth, low-dose buprenorphine is being recognized as one method to avoid moderate withdrawal symptoms prior to treatment. Lastly, significant gaps exist in human experimental data concerning the effects of HPSO on key factors critical for treating OUD-craving, withdrawal symptoms, and pain. Conclusions: Current evidence supports MOUD safety and effectiveness in reducing nonmedical opioid use. Further research is needed to explore HPSO’s influence on the acute factors preceding nonmedical opioid use, such as cravings, withdrawal symptoms, and pain. This research could inform the optimization of MOUD dosing strategies. Achieving consensus and harmonizing data across clinical and research protocols could diminish variability, enhancing our understanding of HPSOs effect on MOUD treatment outcomes.

7 July 2020 in Case Reports in Psychiatry
Verified
Journal Article
Open access
PDF file
SASamuel Adeyemo
Samuel Adeyemo
OJOluwole Jegede
Oluwole Jegede
PRPeterson Rabel
Peterson Rabel
SASaad Ahmed
Saad Ahmed
TTTerence Tumenta
Terence Tumenta
KTKhanderker Taher
Khanderker Taher
Tachycardia emergent from clozapine treatment is usually transient, often missed, unreported, and therefore frequently goes untreated resulting in possible premature discontinuation of an otherwise effective treatment. Clozapine-induced tachycardia results from direct effects on the sympathetic nervous system including the blockade of cardiac muscarinic M2 receptors, presynaptic α2 adrenoceptors, and indirect activation of the β adrenoceptors. Unfortunately, there are no clear guidelines for monitoring or treating tachycardia induced by clozapine. We present a case of a 55-year-old man with treatment-resistant schizophrenia initiated on clozapine who developed persistent tachycardia and right bundle branch block in the course of treatment. Tachycardia persisted despite treatment with metoprolol and necessitated a transfer to the intensive care unit. A reduction in clozapine dose with the addition of adjunctive antipsychotic(lurasidone) stabilized the patient’s heart rate. This case highlights the need for consistent physical examination and a multidisciplinary-based treatment approach for patients on clozapine. The case also suggests that clozapine dose reduction and combination antipsychotic treatments may preclude the need to discontinue clozapine in patients with persistent tachycardia.